{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T10:24:18Z","timestamp":1777717458334,"version":"3.51.4"},"reference-count":43,"publisher":"SAGE Publications","issue":"5","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Toxicol"],"published-print":{"date-parts":[[2005,9]]},"abstract":"<jats:p>This study was conducted as part of the International Life Sciences Institute (ILSI) program to evaluate the carcinogenic potential of clofibrate, a nongenotoxic, peroxisome proliferator-activated receptor (PPAR) \u03b1 agonist following oral administration to Tg.AC (transgenic) and wild-type FVB (nontransgenic) mice for a minimum for 6 months. Clofibrate was well tolerated at doses up to 500 (males) and 650 (females) mg\/kg\/day. Oral administration of clofibrate to Tg.AC or FVB (wild-type) male and female mice for 6 months did not result in the increased formation of neoplastic lesions. Epithelial hyperplasia in the urinary bladder (Tg.AC and FVB) and prostate gland (Tg.AC only), and interstitial-cell hyperplasia in the testes (Tg.AC) were noted at 500 mg\/kg\/day. Non-neoplastic nonproliferative findings included hepatic hypertrophy and hematopoietic changes (myeloid hyperplasia, myelodysplasia, lymphoid depletion, and erythropoiesis) in Tg.AC and FVB mice of both sexes; reproductive (cystic degeneration and dilatation, hypospermia, spermatocele, dilated inspissated protein) and urogenital (tubular-cell hypertrophy, degenerative\/regenerative nephropathy, necrosis\/fibrosis) changes in Tg.AC and FVB male mice; congestion in the lung in male Tg.AC mice; gall bladder dilatation in female Tg.AC mice; and adrenal (intracellular lipofuscinosis and atrophy) and heart (eosinophillic myofibers) findings in Tg.AC mice of both sexes and in female FVB mice. The results of this study indicate that the clofibrate is not carcinogenic when administered to Tg.AC mice by oral gavage for 6 months at doses up to 500 (males) and 650 (females) mg\/kg\/day, which did produce liver hypertrophy.<\/jats:p>","DOI":"10.1080\/10915810500208264","type":"journal-article","created":{"date-parts":[[2005,10,28]],"date-time":"2005-10-28T11:48:42Z","timestamp":1130500122000},"page":"313-325","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of the Carcinogenic Potential of Clofibrate in FVB\/Tg.AC Mouse After Oral Administration\u2014Part I"],"prefix":"10.1177","volume":"24","author":[{"given":"Carla E.","family":"Torrey","sequence":"first","affiliation":[{"name":"GlaxoSmithKline, Safety Assessment, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry G.","family":"Wall","sequence":"additional","affiliation":[{"name":"Experimental Pathology Laboratories, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James A.","family":"Campbell","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Safety Assessment, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Puntipa","family":"Kwanyuen","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Safety Assessment, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debie J.","family":"Hoivik","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Safety Assessment, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Miller","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Safety Assessment, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane S.","family":"Allen","sequence":"additional","affiliation":[{"name":"Jane Allen Consulting, Inc., Raleigh, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel J.","family":"Jayo","sequence":"additional","affiliation":[{"name":"Pathology Associates Inc., Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krzysztof","family":"Selinger","sequence":"additional","affiliation":[{"name":"Forest Laboratories Inc., Bioanalytical and Drug Metabolism Department, Farmingdale, New York"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul M.","family":"Savina","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Drug Metabolism and Pharmacokinetics, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Santostefano","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Safety Assessment, Research Triangle Park, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2005,9,1]]},"reference":[{"key":"b1-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/15287398909531232"},{"key":"b2-0240313","first-page":"978","volume":"15","author":"Ando KS","year":"1992","journal-title":"Cancer Res"},{"key":"b3-0240313","doi-asserted-by":"publisher","DOI":"10.1007\/BF01062139"},{"key":"b4-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/01926230309800"},{"key":"b5-0240313","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2744(199709)20:1<108::AID-MC12>3.0.CO;2-5"},{"key":"b6-0240313","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-0322"},{"key":"b7-0240313","doi-asserted-by":"publisher","DOI":"10.1354\/vp.37-5-422"},{"key":"b8-0240313","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1979.tb01642.x"},{"key":"b9-0240313","volume-title":"Introduction to statistical analysis","author":"Dixon W","year":"1951"},{"key":"b10-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/00401706.1964.10490181"},{"key":"b11-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1955.10501294"},{"key":"b12-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/019262301753178483"},{"key":"b13-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/10915810500210385"},{"key":"b14-0240313","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgh182"},{"key":"b15-0240313","doi-asserted-by":"publisher","DOI":"10.1093\/toxsci\/64.2.192"},{"key":"b16-0240313","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/41.1-2.133"},{"key":"b17-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/10408440490464705"},{"key":"b18-0240313","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4274(93)90013-N"},{"key":"b19-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/713608372"},{"key":"b20-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/15287398209530296"},{"key":"b21-0240313","doi-asserted-by":"publisher","DOI":"10.1177\/019262339802600406"},{"key":"b22-0240313","first-page":"6739","volume":"48","author":"Marsman DS","year":"1988","journal-title":"Cancer Res"},{"key":"b23-0240313","first-page":"19","author":"NDA","year":"1993","journal-title":"Summary of basis for approval, Food and Drug Administration"},{"key":"b24-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/10915810500210278"},{"key":"b25-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/10915810500210401"},{"key":"b26-0240313","first-page":"1211","volume":"36","author":"Reddy JK","year":"1976","journal-title":"Cancer Res"},{"key":"b27-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/019262301753178438"},{"key":"b28-0240313","doi-asserted-by":"publisher","DOI":"10.1002\/pros.10058"},{"key":"b29-0240313","doi-asserted-by":"publisher","DOI":"10.2307\/2529789"},{"key":"b30-0240313","volume-title":"Presented at Drug Information Association 40th Annual Meeting","author":"Storer RD","year":"2004"},{"key":"b31-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/019262301753178465"},{"key":"b32-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/019262301753178492"},{"key":"b33-0240313","doi-asserted-by":"publisher","DOI":"10.1289\/ehp.95103942"},{"key":"b34-0240313","doi-asserted-by":"publisher","DOI":"10.1016\/S0165-1110(96)90016-0"},{"key":"b35-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/019262301753178474"},{"key":"b36-0240313","doi-asserted-by":"publisher","DOI":"10.1016\/0378-4274(87)90133-0"},{"key":"b37-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/10915810500210237"},{"key":"b38-0240313","doi-asserted-by":"publisher","DOI":"10.1080\/10915810500208199"},{"key":"b39-0240313","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1747.1998.00237.x"},{"key":"b40-0240313","first-page":"263","volume":"29","author":"Urano K","year":"2001","journal-title":"Toxicol Pathol"},{"key":"b41-0240313","first-page":"103","volume":"27","author":"Williams DA","year":"1971","journal-title":"A test for differences between treatment means when several dose levels are compared with a zero dose control Biometrics"},{"key":"b42-0240313","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra041001"},{"key":"b43-0240313","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600820718"}],"container-title":["International Journal of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/10915810500208264","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1080\/10915810500208264","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1080\/10915810500208264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T10:22:13Z","timestamp":1777458133000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1080\/10915810500208264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["10.1080\/10915810500208264"],"URL":"https:\/\/doi.org\/10.1080\/10915810500208264","relation":{},"ISSN":["1091-5818","1092-874X"],"issn-type":[{"value":"1091-5818","type":"print"},{"value":"1092-874X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,9]]}}}